tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Skye Bioscience: ENHANZE Partnership Unlocks Nimacimab Dosing, De-Risks Phase 2b Path and Supports Buy Rating
PremiumRatingsSkye Bioscience: ENHANZE Partnership Unlocks Nimacimab Dosing, De-Risks Phase 2b Path and Supports Buy Rating
24d ago
Skye Bioscience, Halozyme enter collaboration, license agreement
Premium
The Fly
Skye Bioscience, Halozyme enter collaboration, license agreement
25d ago
Halozyme, Skye Bioscience announce global collaboration, license agreement
Premium
The Fly
Halozyme, Skye Bioscience announce global collaboration, license agreement
25d ago
Skye Bioscience Reports Promising Q3 2025 Results
PremiumCompany AnnouncementsSkye Bioscience Reports Promising Q3 2025 Results
3M ago
Skye Bioscience reports Q3 EPS (32c), consensus (32c)
Premium
The Fly
Skye Bioscience reports Q3 EPS (32c), consensus (32c)
3M ago
SKYE Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
SKYE Earnings this Week: How Will it Perform?
3M ago
Skye Bioscience downgraded to Hold from Buy at Craig-Hallum
PremiumThe FlySkye Bioscience downgraded to Hold from Buy at Craig-Hallum
4M ago
Fifth Third buying Comerica, AMD gets OpenAI boost: Morning Buzz
Premium
The Fly
Fifth Third buying Comerica, AMD gets OpenAI boost: Morning Buzz
4M ago
Promising Phase IIa Results and Favorable Safety Profile Drive Buy Rating for Skye Bioscience’s Nimacimab
Premium
Ratings
Promising Phase IIa Results and Favorable Safety Profile Drive Buy Rating for Skye Bioscience’s Nimacimab
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100